Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
This surpasses the number of approvals supported in 2020
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
